Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
NCT02704403 · Genfit · PHASE3 · terminated · last registry update 2022-03-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study did not meet the predefined primary surrogate efficacy endpoint, no safety issues identified” | – | Registry record, Genfit |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPARA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-03-03Phase 3 first posted: Tanta University, Mesalamine + Fenofibrate 160mg (NCT05753267)
- 2023-03-02Phase 3 first posted: Xijing Hospital of Digestive Diseases, Placebo Combined With Ursodeoxycholic Acid + Fenofibrate Combined With Ursodeoxycholic Acid (NCT05751967)
- 2023-03-01Phase 3 first posted: Xijing Hospital of Digestive Diseases, Fenofibrate 200mg + Placebo (NCT05749822)
- 2023-02-27Results posted on the registry: University of Pennsylvania, a drug against PPARA (NCT04517396)
- 2023-02-24Results posted on the registry: University of Guadalajara, Berberine + Bezafibrate (NCT02548832)
- 2023-02-08Also stopped (suspended): Zydus Therapeutics Inc., Saroglitazar Magnesium 1 mg + Saroglitazar Magnesium 2 mg (NCT03097107)
- 2022-11-30Results posted on the registry: Kowa Research Institute, Inc., K-877 + Fenofibrate (NCT03001817)
- 2022-11-03Results posted on the registry: Genfit, GFT505 80mg + GFT505 120mg (NCT01694849)
- 2022-10-28Results posted on the registry: Kowa Research Institute, Inc., K-877 + Fenofibrate (NCT03011450)
- 2022-04-25Results posted on the registry: Amarin Pharma Inc., AMR101 (ethyl icosapentate) - 4 g/day + AMR101 (ethyl icosapentate) - 2 g/day (NCT01047501)
- 2022-04-25Results posted on the registry: Amarin Pharma Inc., AMR101 (ethyl icosapentate) - 4 g/day + AMR101 (ethyl icosapentate) - 2 g/day (NCT01047683)
- 2022-04-14Results posted on the registry: Amarin Pharma Inc., AMR101 + Placebo (NCT01492361)
- 2022-02-08Results posted on the registry: Medical University of South Carolina, Fenofibrate (NCT03829514)
- 2022-02-02Results posted on the registry: Gilead Sciences, SEL + FIR (NCT02781584)
- 2021-12-13Results posted on the registry: Merck Sharp & Dohme LLC, IMI/REL FDC (NCT03230916)
- 2021-11-24Phase 3 first posted: Zydus Therapeutics Inc., Saroglitazar Magnesium 1 mg + Saroglitazar Magnesium 2 mg (NCT05133336)
- 2021-10-29Also stopped (terminated): The Mind Research Network, Gemfibrozil 600 MG + Placebo oral capsule (NCT03539432)
- 2021-10-28Results posted on the registry: Genfit, Elafibranor 80mg + Elafibranor 120mg (NCT03883607)
- 2021-10-28Also stopped (terminated): Genfit, Elafibranor 80mg + Elafibranor 120mg (NCT03883607)
- 2021-10-18Results posted on the registry: The Mind Research Network, Gemfibrozil 600 MG + Placebo oral capsule (NCT03539432)
- 2021-09-17Also stopped (withdrawn): Beijing 302 Hospital, Fenofibrate + UDCA (NCT02965911)
- 2021-08-10Phase 3 first posted: Kowa Company, Ltd., K-877 0.1 mg tablet + Fenofibrate 200 mg capsule (NCT04998981)
- 2021-05-11Phase 3 first posted: Laboratorios Silanes S.A. de C.V., Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose + Atorvastatin (Lipitor ®) (NCT04882293)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision